<?xml version="1.0"?>
<feed xmlns="http://www.w3.org/2005/Atom" xml:lang="en-GB">
	<id>https://stockhub.co/index.php?action=history&amp;feed=atom&amp;title=Tricida%2C_Inc.</id>
	<title>Tricida, Inc. - Revision history</title>
	<link rel="self" type="application/atom+xml" href="https://stockhub.co/index.php?action=history&amp;feed=atom&amp;title=Tricida%2C_Inc."/>
	<link rel="alternate" type="text/html" href="https://stockhub.co/index.php?title=Tricida,_Inc.&amp;action=history"/>
	<updated>2026-05-26T12:30:59Z</updated>
	<subtitle>Revision history for this page on the wiki</subtitle>
	<generator>MediaWiki 1.43.5</generator>
	<entry>
		<id>https://stockhub.co/index.php?title=Tricida,_Inc.&amp;diff=66538&amp;oldid=prev</id>
		<title>95.149.241.133: Created page with &quot;== Summary&lt;ref&gt;Source: Yahoo Finance.&lt;/ref&gt; ==  Tricida, Inc. operates as a pharmaceutical company. It focuses on the development and commercialization of veverimer (TRC101), a non-absorbed orally-administered polymer that has completed Phase III trial to treat metabolic acidosis in patients with chronic kidney disease by binding and removing acid from the gastrointestinal track. The company was incorporated in 2013 and is headquartered in South San Francisco, California...&quot;</title>
		<link rel="alternate" type="text/html" href="https://stockhub.co/index.php?title=Tricida,_Inc.&amp;diff=66538&amp;oldid=prev"/>
		<updated>2022-09-21T07:40:04Z</updated>

		<summary type="html">&lt;p&gt;Created page with &amp;quot;== Summary&amp;lt;ref&amp;gt;Source: Yahoo Finance.&amp;lt;/ref&amp;gt; ==  Tricida, Inc. operates as a pharmaceutical company. It focuses on the development and commercialization of veverimer (TRC101), a non-absorbed orally-administered polymer that has completed Phase III trial to treat metabolic acidosis in patients with chronic kidney disease by binding and removing acid from the gastrointestinal track. The company was incorporated in 2013 and is headquartered in South San Francisco, California...&amp;quot;&lt;/p&gt;
&lt;p&gt;&lt;b&gt;New page&lt;/b&gt;&lt;/p&gt;&lt;div&gt;== Summary&amp;lt;ref&amp;gt;Source: Yahoo Finance.&amp;lt;/ref&amp;gt; ==&lt;br /&gt;
&lt;br /&gt;
Tricida, Inc. operates as a pharmaceutical company. It focuses on the development and commercialization of veverimer (TRC101), a non-absorbed orally-administered polymer that has completed Phase III trial to treat metabolic acidosis in patients with chronic kidney disease by binding and removing acid from the gastrointestinal track. The company was incorporated in 2013 and is headquartered in South San Francisco, California.&lt;br /&gt;
&lt;br /&gt;
== References and notes == &lt;br /&gt;
[[Category:Thesis]]&lt;br /&gt;
__INDEX__&lt;/div&gt;</summary>
		<author><name>95.149.241.133</name></author>
	</entry>
</feed>